RMD
ResMed Inc. · Healthcare · Medical - Instruments & Supplies
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 157 | +2 | 75.82M | $14.78B | +7 | −6 |
| Q1 2026 | 159 | +3 | 74.11M | $16.62B | +5 | −3 |
| Q4 2025 | 155 | -2 | 83.70M | $20.16B | +1 | −2 |
| Q3 2025 | 21 | 0 | 49.43M | $13.53B | n/a | −1 |
| Q2 2025 | 19 | +1 | 44.83M | $11.56B | +1 | n/a |
| Q1 2025 | 15 | -1 | 12.96M | $2.90B | n/a | −1 |
| Q4 2024 | 16 | -2 | 12.69M | $2.90B | n/a | −2 |
| Q3 2024 | 17 | +2 | 6.96M | $1.70B | +2 | n/a |
| Q2 2024 | 15 | n/a | 5.93M | $1.13B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.48M | n/a | $664.08M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 436.06K | n/a | $83.47M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 432.08K | n/a | $82.71M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 413.92K | n/a | $79.23M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 403.75K | n/a | $77.29M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 219.60K | n/a | $42.04M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 172.78K | n/a | $33.07M | 0.1% | n/c | 1 | SEC ↗ ×4 |
| 8 | Bridgewater Associates ✦ | 166.11K | n/a | $31.80M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | Baillie Gifford ✦ | 52.56K | n/a | $10.06M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Gotham Asset Management ✦ | 44.20K | n/a | $8.46M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 44.15K | n/a | $8.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Fisher Asset Management ✦ | 25.16K | n/a | $4.82M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 22.14K | n/a | $4.24M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 18.48K | n/a | $3.54M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 2.20K | n/a | $421,124 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 932 holders, 96.37M shares, $21.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 4.99K sh · $1.13M
Officer, Director · 4.99K sh · $1.11M
Director · 970 sh · $227,688
Officer, Director · 4.99K sh · $1.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology